GLP-1 Weight Loss Management in Chanhassen, MN

Semaglutide and tirzepatide are GLP-1 medications that mimic the effects of natural hormones involved in appetite control and insulin regulation. Tirzepatide also acts on a second hormone receptor called GIP. Both medications slow gastric emptying and reduce hunger signals while helping your body release insulin when blood sugar rises, which makes it easier to feel full and eat less. This dual-action support helps patients manage both blood sugar and weight effectively.

Weight loss results vary by individual, but clinical studies show that many patients can lose up to 15–20% of their body weight with consistent use and healthy lifestyle changes. Our team will help set realistic goals based on your unique health profile and track your progress closely.

Most patients begin to notice weight loss within the first few weeks, with more significant results typically appearing after 8 to 12 weeks of consistent use. Long-term success is supported by ongoing treatment, nutrition counseling, and follow-up visits with our providers.

The most common side effects are mild and typically improve with time. These include nausea, diarrhea or constipation, fatigue, and decreased appetite. Serious side effects are rare but will be discussed in detail during your consultation.

While both medications can be effective for weight management and blood sugar control, they have some key differences. Semaglutide is a GLP-1 receptor agonist that has been used for years to help patients manage appetite and improve metabolic health. Tirzepatide works on both GLP-1 and GIP receptors, offering a slightly different mechanism of action. In clinical trials, tirzepatide has generally produced greater average weight loss, while semaglutide has a longer track record. We will help you choose the right GLP-1 based on your health history and goals.

Semaglutide membership: $399/mo

Tirzepatide membership: $499/mo

*Pricing may vary depending on dosage, frequency, and length of treatment.

Insurance coverage for semaglutide or tirzepatide can vary based on your provider and medical history. While some plans may cover part of the cost, many choose to pay out of pocket for weight loss support. Our team can help verify your benefits and discuss financing options if needed.

Ozempic is one brand of semaglutide, which belongs to the GLP-1 class of medications. Ozempic is FDA-approved for type 2 diabetes, and Wegovy is the semaglutide brand FDA-approved for chronic weight management. The GLP-1 class also includes tirzepatide (sold as Mounjaro and Zepbound) and liraglutide. Compounded semaglutide and tirzepatide contain the same active ingredients but are not FDA-approved products.

GLP-1 medications are not recommended if you or a family member has a history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). They are also generally avoided during pregnancy and breastfeeding. We will review any history of pancreatitis or gallbladder disease before prescribing.

Brand-name GLP-1 medications for weight management are FDA-approved for adults with a BMI of 30 or higher, or 27 or higher with at least one weight-related health condition. We will review your BMI and health history to determine if GLP-1 treatment is appropriate for you.

Many people regain some of their lost weight after stopping, since appetite tends to return to its previous level. Some patients continue on a maintenance dose, and others taper off gradually with ongoing lifestyle support. We will help you plan for the long term so you can protect your progress.

Fried or high-fat foods and very sugary foods can make nausea worse, and large portions can leave you uncomfortably full. Many patients feel best eating smaller meals built around protein, and drinking plenty of water helps too.

Because GLP-1 medications slow digestion, they can affect how some oral medications are absorbed. Taking them with insulin or sulfonylureas can also raise the risk of low blood sugar. Share your full medication list with us so we can check for interactions.